Biosimilars: development and investigation using achievements in modern biotechnology
Biosimilars are biological drug products that have an equivalent clinical profile with innovator biotherapeutics but are developed under a reduced program. To this end, specific comparability approaches are followed based on reverse engineering that involves a thorough analysis of the innovator biot...
Guardado en:
Autores principales: | R. R. Niyazov, M. A. Dranitsyna, A. N. Vasiliev, E. V. Gavrishina |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3890df950eda4cfaab3a564c6fd838b2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biosimilars: presumption of guilt
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011) -
Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
por: Irina A. Proskurina, et al.
Publicado: (2016) -
Russian association of endocrinologist draft recommendation on insulin biosimilars using
por: I. I. Dedov, et al.
Publicado: (2021) -
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
por: Alexander Y. Mayorov, et al.
Publicado: (2020) -
Assessment the equivalence of the bioanalogue insulin lizpro biphasic 25 (Geropharm-bio, Russia) and Humalog® Mix 25 (Lilly France, France) using the euglycemic hyperinsulinum clamp method on healthy volonters
por: Alexander Y. Mayorov, et al.
Publicado: (2018)